David this company is a fire sale here. Look at the Cohort1 results. Cohort2 was a bit of a mess one reason for the current price. The complete lack of TOX. Given go ahead for phase2 Enough money for phase2 Fast track Animal study showed improvement when mouse was still injecting with TOX. The previous generation drug Davanat efficacy. GALT will be in phase2 next year you think the price will be lower or higher then?
News 
Market Data 
Discover 
